Seizures were not identified as a recognised adverse effect in the pivotal STEP (Semaglutide Treatment Effect in People with obesity) clinical trial programme, which enrolled over 4,500 participants and formed the basis for regulatory approval
The SUSTAIN 2 trial has shown that semaglutide at both doses, 0.5 and 1 mg, is superior at improving glycemic control in subjects with type 2 diabetes, compared with sitagliptin, and showed a reduction of 1.3% and 1.6%, respectively, from the baseline HbA 1c of 8.1%, Dr
Combination therapies: Combining GLP-1 agonists with other medications, such as GIP receptor agonists (as in tirzepatide), may offer enhanced benefits across multiple health parameters
Without product traceability, you cannot be certain of the substances origin or its exact chemical composition